WNK2 and esophageal cancer: BMS-536924 has been reported to effectively inhibit an activation of Akt and mitogen-activated protein kinases (MAPK), thereby enhancing 5‐fluorouracil (5‐FU)-induced apoptosis in a manner proportional to the dose administered, along with exhibiting anti-neoplastic effects in esophageal cancer cells (76).